155 related articles for article (PubMed ID: 12747576)
1. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine pretreatment attenuates methamphetamine-induced dopamine toxicity.
Kita T; Saraya T; Konishi N; Matsunari Y; Shimada K; Nakamura M; O'Hara K; Wagner GC; Nakashima T
Pharmacol Toxicol; 2003 Feb; 92(2):71-80. PubMed ID: 12747576
[TBL] [Abstract][Full Text] [Related]
2. Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity.
Battaglia G; Gesi M; Lenzi P; Busceti CL; Soldani P; Orzi F; Rampello L; Nicoletti F; Ruggieri S; Fornai F
Ann N Y Acad Sci; 2002 Jun; 965():254-66. PubMed ID: 12105101
[TBL] [Abstract][Full Text] [Related]
3. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
4. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
5. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice.
Chang FW; Wang SD; Lu KT; Lee EH
Brain Res Bull; 1993; 31(3-4):253-66. PubMed ID: 7683960
[TBL] [Abstract][Full Text] [Related]
6. Methamphetamine-induced striatal dopamine release, behavior changes and neurotoxicity in BALB/c mice.
Kita T; Matsunari Y; Saraya T; Shimada K; O'Hara K; Kubo K; Wagner GC; Nakashima T
Int J Dev Neurosci; 2000 Oct; 18(6):521-30. PubMed ID: 10884597
[TBL] [Abstract][Full Text] [Related]
7. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
8. Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice.
Moy LY; Albers DS; Sonsalla PK
Brain Res; 1998 Apr; 790(1-2):264-9. PubMed ID: 9593931
[TBL] [Abstract][Full Text] [Related]
9. Relationship between methamphetamine-induced dopamine release, hyperthermia, self-injurious behaviour and long term dopamine depletion in BALB/c and C57BL/6 mice.
Halladay AK; Kusnecov A; Michna L; Kita T; Hara C; Wagner GC
Pharmacol Toxicol; 2003 Jul; 93(1):33-41. PubMed ID: 12828572
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effect of neuronal nitric oxide synthase inhibitor (7-nitroindazole) against MPTP neurotoxicity in mice.
Muramatsu Y; Kurosaki R; Mikami T; Michimata M; Matsubara M; Imai Y; Kato H; Itoyama Y; Araki T
Metab Brain Dis; 2002 Sep; 17(3):169-82. PubMed ID: 12322787
[TBL] [Abstract][Full Text] [Related]
11. The neurotoxicant MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: evidence for glial response to injury.
Reinhard JF; Miller DB; O'Callaghan JP
Neurosci Lett; 1988 Dec; 95(1-3):246-51. PubMed ID: 3265770
[TBL] [Abstract][Full Text] [Related]
12. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
Sriram K; Miller DB; O'Callaghan JP
J Neurochem; 2006 Feb; 96(3):706-18. PubMed ID: 16405514
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of riluzole on MPTP-induced depletion of dopamine and its metabolite content in mice.
Araki T; Kumagai T; Matsubara M; Ido T; Imai Y; Itoyama Y
Metab Brain Dis; 2000 Sep; 15(3):193-201. PubMed ID: 11206588
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.
Battaglia G; Busceti CL; Cuomo L; Giorgi FS; Orzi F; De Blasi A; Nicoletti F; Ruggieri S; Fornai F
Neuropharmacology; 2002 Mar; 42(3):367-73. PubMed ID: 11897115
[TBL] [Abstract][Full Text] [Related]
16. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum.
Chan P; Langston JW; Di Monte DA
J Pharmacol Exp Ther; 1993 Dec; 267(3):1515-20. PubMed ID: 8263813
[TBL] [Abstract][Full Text] [Related]
17. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
18. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity.
Fornai F; Battaglia G; Gesi M; Giorgi FS; Orzi F; Nicoletti F; Ruggieri S
Brain Res; 2000 Dec; 887(1):110-7. PubMed ID: 11134595
[TBL] [Abstract][Full Text] [Related]
19. Biochemical alterations of the striatum in an MPTP-treated mouse model of Parkinson's disease.
Kuroiwa H; Yokoyama H; Kimoto H; Kato H; Araki T
Metab Brain Dis; 2010 Jun; 25(2):177-83. PubMed ID: 20431930
[TBL] [Abstract][Full Text] [Related]
20. Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Mori A; Ohashi S; Nakai M; Moriizumi T; Mitsumoto Y
Neurosci Res; 2005 Mar; 51(3):265-74. PubMed ID: 15710490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
